As we have seen from various reports, targeting the SHH pathway for inhibition using vismodegib led to increased frequency of quiescent Sox2+ medulloblastoma cells in the Ptch+/− mouse models [45]. The gene discussed is SOX2; the disease is medulloblastoma.